NEOG

Company Overview — What Does NEOGEN CORP Do?

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan. NEOGEN CORP (NEOG) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John E. Adent and employs approximately 2,110 people, headquartered in Lansing, Michigan. With a market capitalization of $2.0B, NEOG is one of the notable companies in the Healthcare sector.

NEOGEN CORP (NEOG) Stock Rating — Reduce (April 2026)

As of April 2026, NEOGEN CORP receives a Reduce rating with a composite score of 39.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NEOG ranks #2,722 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NEOGEN CORP ranks #369 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NEOG Stock Price and 52-Week Range

NEOGEN CORP (NEOG) currently trades at $9.37. The stock lost $0.67 (6.6%) in the most recent trading session. The 52-week high for NEOG is $11.43, which means the stock is currently trading -18.0% from its annual peak. The 52-week low is $3.87, putting the stock 142.1% above its annual trough. Recent trading volume was 4.8M shares, reflecting moderate market activity.

Is NEOG Overvalued or Undervalued? — Valuation Analysis

NEOGEN CORP (NEOG) carries a value factor score of 36/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.03x, versus the sector average of 2.75x. The price-to-sales ratio is 2.45x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, NEOG trades at 13.94x EV/EBITDA, versus 6.34x for the sector.

At current multiples, NEOGEN CORP trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

NEOGEN CORP Profitability — ROE, Margins, and Quality Score

NEOGEN CORP (NEOG) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -21.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -13.3% versus the sector average of -33.1%.

On a margin basis, NEOGEN CORP reports gross margins of 47.9%, compared to 71.5% for the sector. The operating margin is -51.4% (sector: -66.1%). Net profit margin stands at -48.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 3.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NEOG Debt, Balance Sheet, and Financial Health

NEOGEN CORP has a debt-to-equity ratio of 60.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.91x, indicating strong short-term liquidity.

NEOG has a beta of 1.16, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for NEOGEN CORP is 49/100, reflecting average volatility within the normal range for its sector.

NEOGEN CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, NEOGEN CORP reported revenue of $886M and earnings per share (EPS) of $-0.07. Net income for the quarter was $-447M. Gross margin was 47.9%. Operating income came in at $-474M.

In Q2 2026, NEOGEN CORP reported revenue of $225M and earnings per share (EPS) of $-0.07. Net income for the quarter was $-16M. Gross margin was 47.5%. Revenue grew -2.8% year-over-year compared to Q2 2025. Operating income came in at $-5M.

In Q1 2026, NEOGEN CORP reported revenue of $209M and earnings per share (EPS) of $0.17. Net income for the quarter was $36M. Gross margin was 45.4%. Revenue grew -3.6% year-over-year compared to Q1 2025. Operating income came in at $-16M.

In FY 2025, NEOGEN CORP reported revenue of $895M and earnings per share (EPS) of $-5.03. Net income for the quarter was $-1.09B. Gross margin was 47.1%. Revenue grew -3.2% year-over-year compared to FY 2024. Operating income came in at $-1.06B.

Over the past 8 quarters, NEOGEN CORP has experienced revenue contraction from $924M to $886M. Investors analyzing NEOG stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NEOG Dividend Yield and Income Analysis

NEOGEN CORP (NEOG) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NEOG Momentum and Technical Analysis Profile

NEOGEN CORP (NEOG) has a momentum factor score of 62/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

NEOG vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, NEOGEN CORP (NEOG) ranks #369 out of 838 stocks based on the Blank Capital composite score. This places NEOG in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NEOG against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NEOG vs S&P 500 (SPY) comparison to assess how NEOGEN CORP stacks up against the broader market across all factor dimensions.

NEOG Next Earnings Date

No upcoming earnings date has been announced for NEOGEN CORP (NEOG) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NEOG? — Investment Thesis Summary

The quantitative profile for NEOGEN CORP suggests caution. The quality score of 31/100 flags below-average profitability. The value score of 36/100 indicates premium valuation. Price momentum is positive at 62/100, suggesting the trend favors buyers.

In summary, NEOGEN CORP (NEOG) earns a Reduce rating with a composite score of 39.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NEOG stock.

Related Resources for NEOG Investors

Explore more research and tools: NEOG vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NEOG head-to-head with peers: NEOG vs AZN, NEOG vs SLGL, NEOG vs VMD.